Artera vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 52)
Artera logo

Artera

GrowthHealthTech

Patient Communication Platform

Artera orchestrates automated patient outreach across appointment reminders, care gap campaigns, and post-visit follow-up, coordinating communications across a health system's service lines.

AI VisibilityBeta
Overall Score
C52
Category Rank
#320 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
50
Perplexity
58
Gemini
46

About

Artera's patient communication platform sits above EHR and practice management systems to orchestrate outbound and inbound messaging across a health system's multiple service lines — preventing the communication chaos that occurs when each department independently sends texts and reminders that overwhelm patients and create conflicting instructions. The platform uses AI to personalize message timing, channel (SMS, voice, email), and language to maximize patient response rates while suppressing redundant outreach.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

52
Overall Score
90
#320
Category Rank
#2
71
AI Consensus
83
stable
Trend
stable
50
ChatGPT
92
58
Perplexity
93
46
Gemini
89
51
Claude
96
47
Grok
95

Key Details

Category
Patient Communication Platform
Enterprise
Tier
Growth
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Artera
Patient Communication Platform

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.